Company profile

Disc Medicine, Inc.

Pipeline4 assets

bitopertinGlyT1 / Small Molecule / Hematology
Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)Phase 3OngoingGlobalDiamond-Blackfan AnemiaPhase 2OngoingUS
DISC-0974DISC-0974 / Hemojuvelin (HJV) / Monoclonal Antibody / Hematology
Anemia of Myelofibrosis (MF)Phase 2OngoingGlobalAnemia of Chronic Kidney Disease (CKD)Phase 1/Phase 2OngoingGlobalAnemia of Inflammatory Bowel Disease (IBD)Phase 2PlannedGlobal
DISC-3405DISC-3405 / TMPRSS6 (Matriptase-2) / Monoclonal Antibody / Hematology
Polycythemia Vera (PV)Phase 2OngoingGlobalSickle Cell Disease (SCD)Phase 1bOngoingGlobal
DISC-0998DISC-0998 / Hemojuvelin (HJV) / Monoclonal Antibody / Hematology
Inflammatory-disease-associated anemiaPreclinicalOngoingGlobal

Latest news12 items

May 12, 2026

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT study (patient survey on life and health impact of disease), and DISC-3405

Presentation / Abstract • Phase 2EHA oral presentation Fri, Jun 12, 2026, 5:15 PM CEST

May 11, 2026

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company

May 5, 2026

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026 Updated data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) to be shared at the American Society of Clinical Oncology (ASCO) Annual

Enrollment • Phase 3

Apr 21, 2026

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will

Presentation / Abstract • Phase 2

Mar 26, 2026

Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria

Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and physician demand Results of the APOLLO study are expected in Q4 2026 WATERTOWN, Mass., March 26, 2026

Enrollment • Phase 3

Feb 26, 2026

Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026 Initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF)

Feb 24, 2026

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company

Feb 13, 2026

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the PPIX biomarker in protoporphyria FDA indicated a need to see the results of the ongoing Phase 3

Enrollment • Phase 3

Jan 12, 2026

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the

Jan 12, 2026

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA review Updated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia expected in H2 2026, followed by an End of Phase 2 Meeting Initial data from the

Jan 7, 2026

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John

Dec 6, 2025

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc.

Trial Results • Phase 2